Guardant Health (NASDAQ:GH) CTO Sells 7,738 Shares

Guardant Health, Inc. (NASDAQ:GH) CTO Darya Chudova sold 7,738 shares of the stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $178.00, for a total value of $1,377,364.00. Following the transaction, the chief technology officer owned 70,635 shares of the company’s stock, valued at $12,573,030. The trade was a 9.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Guardant Health Price Performance

NASDAQ:GH traded up $8.20 on Thursday, reaching $183.10. 1,858,277 shares of the company’s stock were exchanged, compared to its average volume of 2,252,181. The firm has a market cap of $24.57 billion, a price-to-earnings ratio of -52.46 and a beta of 1.57. The stock has a fifty day simple moving average of $160.33 and a 200-day simple moving average of $126.47. Guardant Health, Inc. has a 52 week low of $55.38 and a 52 week high of $183.51.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.34. The business had revenue of $334.98 million during the quarter, compared to the consensus estimate of $314.23 million. The business’s revenue for the quarter was up 44.3% on a year-over-year basis. During the same period last year, the firm earned ($0.44) EPS. As a group, sell-side analysts predict that Guardant Health, Inc. will post -2.98 EPS for the current year.

Institutional Trading of Guardant Health

A number of hedge funds have recently made changes to their positions in GH. Orbimed Advisors LLC purchased a new position in shares of Guardant Health in the 1st quarter worth about $40,199,000. GSA Capital Partners LLP purchased a new position in shares of Guardant Health during the 2nd quarter valued at about $1,772,000. Ninepoint Partners LP purchased a new position in shares of Guardant Health during the 2nd quarter valued at about $2,853,000. SWS Partners bought a new stake in Guardant Health in the 2nd quarter worth approximately $11,190,000. Finally, Eagle Health Investments LP purchased a new stake in Guardant Health in the second quarter worth approximately $45,112,000. 92.60% of the stock is owned by institutional investors.

Analyst Ratings Changes

GH has been the subject of several recent research reports. Evercore reiterated an “outperform” rating and issued a $200.00 price target on shares of Guardant Health in a research report on Monday, July 6th. BTIG Research reiterated a “buy” rating and set a $195.00 price target on shares of Guardant Health in a research report on Wednesday, September 2nd. Guggenheim raised their price objective on shares of Guardant Health from $160.00 to $190.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Guardant Health in a research note on Friday, July 17th. Finally, Canaccord Genuity Group raised their price target on shares of Guardant Health from $135.00 to $205.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $188.12.

About Guardant Health

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based diagnostic tests designed to help detect cancer, guide treatment decisions and monitor patients over time. Its liquid biopsy technologies analyze tumor-related signals in blood, reducing the need for tissue biopsies in certain clinical and research settings.

The company’s products include Guardant360 tests, which profile advanced cancers and can help identify potentially actionable genomic alterations; Guardant Reveal, which is used to assess residual disease and recurrence risk; and Guardant Shield, a blood-based screening test for colorectal cancer.